Pacific Biosciences of California (PACB:NSD) Analysts rate as Strong Buy, $11.50 target

STA Research
by: STA Research
Pacific Biosciences of California

Based on the Pacific Biosciences stock forecast from 4 analysts, the average analyst PACB stock price target USD 11.50 over the next 12 months. Pacific Biosciences of California’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Pacific Biosciences stock is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, PACB stock price was USD 7.94Pacific PACB stock price has changed by +2.13% over the past week, +3.06% over the past month and -74.04% over the last year.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems.  It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

 

What we like

High market capitalization

Pacific Biosciences stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

Pacific Biosciences stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

 

What we don’t like

High volatility

The total returns for Pacific Biosciences stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

PACB stock price is trading high compared to its peers on a price to earning basis and is above the sector median.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the PACB stock forecast and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

Pacific Biosciences stock had negative total cash flow in the most recent four quarters.

Negative free cash flow

Pacific Biosciences stock had negative total free cash flow in the most recent four quarters.

Low Earnings GrowtH

Pacific Biosciences stock has shown below median earnings growth in the previous 5 years compared to its sector.

Low Revenue Growth

Pacific Biosciences stock has shown below median revenue growth in the previous 5 years compared to its sector.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.